Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.15 USD | -2.83% | +0.98% | -33.89% |
Jun. 05 | Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call | |
May. 14 | Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
Sales 2024 * | 1.46M | Sales 2025 * | 32.08M | Capitalization | 138M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -107M | EV / Sales 2024 * | 95 x |
Net Debt 2024 * | 1M | Net cash position 2025 * | - | EV / Sales 2025 * | 4.29 x |
P/E ratio 2024 * |
-2.15
x | P/E ratio 2025 * |
-1.94
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.66% |
Latest transcript on Syros Pharmaceuticals, Inc.
1 day | -2.83% | ||
1 week | +0.98% | ||
Current month | +0.98% | ||
3 months | -25.69% | ||
6 months | +10.52% | ||
Current year | -33.89% |
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 17-06-11 | |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 5.15 | -2.83% | 74,094 |
24-06-06 | 5.3 | 0.00% | 54,733 |
24-06-05 | 5.3 | +0.76% | 67,572 |
24-06-04 | 5.26 | +2.53% | 102,304 |
24-06-03 | 5.13 | +0.59% | 90,557 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.89% | 138M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- SYRS Stock